Abstract: Journal of Clinical ApheresisVolume 17, Issue 4 p. 207-211 Review Article Plasma exchange: Why we do what we do† Mark E. Brecher, Corresponding Author Mark E. Brecher [email protected] Department of Pathology and Laboratory Medicine, Transfusion Medicine Service, University of North Carolina at Chapel HillDepartment of Pathology and Laboratory Medicine, Transfusion Medicine Service, CB 7600, University of North Carolina Hospitals, 101 Manning Drive, Chapel Hill, NC 27514Search for more papers by this author Mark E. Brecher, Corresponding Author Mark E. Brecher [email protected] Department of Pathology and Laboratory Medicine, Transfusion Medicine Service, University of North Carolina at Chapel HillDepartment of Pathology and Laboratory Medicine, Transfusion Medicine Service, CB 7600, University of North Carolina Hospitals, 101 Manning Drive, Chapel Hill, NC 27514Search for more papers by this author First published: 19 December 2002 https://doi.org/10.1002/jca.10041Citations: 46 † From the Proceedings of the 23rd Annual Meeting of the American Society for Apheresis AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999; 39: 282–288. 10.1046/j.1537-2995.1999.39399219285.x CASPubMedWeb of Science®Google Scholar 2 McCullough J, Chopek M. Therapeutic plasma exchange. Lab Med 1981; 12: 745–753. 10.1093/labmed/12.12.745 Google Scholar 3 Bourke DL, Smith TC. Estimating allowable hemodilution. Anesthesiology 1974; 41: 609–612. 10.1097/00000542-197412000-00015 PubMedWeb of Science®Google Scholar 4 ME Brecher, editor. AABB Technical Manual. Bethesda, MD: American Association of Blood Banks, 14th edition, 2002. Google Scholar 5 Dau PC. Plasmapheresis therapy in myasthenia gravis. Muscle Nerve 1980; 3: 468–482. 10.1002/mus.880030603 CASPubMedWeb of Science®Google Scholar 6 Chirnside A, Uraniak SJ, Powse CV, Keller AJ. Coagulation abnormalties following intensive plasma exchangeon the cell separator, II: Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol 1981; 48: 627–634. 10.1111/j.1365-2141.1981.00627.x PubMedWeb of Science®Google Scholar 7 Sultan Y, Bussel A, Maisonneuve P, et al. Potential danger of thrombosis after plasma exchange in the treatment of patients with immune disease. Transfusion 1979; 19: 588–93 10.1046/j.1537-2995.1979.19580059816.x CASPubMedWeb of Science®Google Scholar 8 Flaum MA, Cuneo RA, Appelbaum FR, Deisseroth AB, Engel WK, Gralnik HR. The hemostatic imbalance of plasma-exchange transfusion. Blood 1979; 54: 694–702. 10.1182/blood.V54.3.694.694 CASPubMedWeb of Science®Google Scholar 9 Wood L, Jacobs P. The effect of therapeutic plasmapheresis on platelet count, coagulation factors, plasmaimmunoglobulin, and complement levels. J Clin Apheresis 1986; 3; 124–128. 10.1002/jca.2920030209 PubMedGoogle Scholar 10 Keller AJ, Chirnside A, Urbaniak SJ. Coagulation abnormalities produced by plasma exchange on the cell separator with special reference to fibrinogen and platelet levels. Br J Haematol 1979; 42: 593–603. 10.1111/j.1365-2141.1979.tb01172.x CASPubMedWeb of Science®Google Scholar 11 Domen E, Kennedy MS, Jones LL, Senhauser DA. Hemostatic imbalances produced by plasma exchanges. Transfusion 1984; 24: 336–339. 10.1046/j.1537-2995.1984.24484275577.x PubMedWeb of Science®Google Scholar 12 Owen HG, Koo A, McAteer M, Brecher ME. Evaluation of platelet loss during TPE on the COBE SPECTRA. J Clin Apheresis 1997; 12: 28. Google Scholar 13 Lasky LC, Finnerty EP, Glenis L, Polesky HF. Protein and colloid osmotic pressure changes with albumin and/or saline replacement during plasma exchange. Transfusion 1984; 24: 256–259. 10.1046/j.1537-2995.1984.24384225034.x CASPubMedWeb of Science®Google Scholar 14 McLeod BC. Sassetti RJ. Stefoski D. Davis FA. Partial plasma protein replacement in therapeutic plasma exchange. J Clin Apheresis 1983; 1: 115–118. 10.1002/jca.2920010209 PubMedGoogle Scholar 15 Owen, HG, Brecher ME. Atypical reactions associated with ACE inhibitors and apheresis. Transfusion. 1994; 34: 891–894. 10.1046/j.1537-2995.1994.341095026976.x CASPubMedWeb of Science®Google Scholar 16 Brecher ME, Owen HG. Washout kinetics of colloidal starch as a partial or full replacement for plasma exchange. J Clin Apheresis 1996; 11: 123–126. 10.1002/(SICI)1098-1101(1996)11:3<123::AID-JCA1>3.0.CO;2-D CASPubMedWeb of Science®Google Scholar 17 Owen HG, Brecher ME, Partial colloid replacement for therapeutic plasma exchange. J Clin Apheresis 1997; 12: 87–92. 10.1002/(SICI)1098-1101(1997)12:2<87::AID-JCA6>3.0.CO;2-5 CASPubMedWeb of Science®Google Scholar 18 Brecher ME, Owen HG, Bandarenko N. Alternatives to albumin: starch replacement for plasma exchange. J Clin Apheresis 1997; 12: 146–153. 10.1002/(SICI)1098-1101(1997)12:3<146::AID-JCA8>3.0.CO;2-A CASPubMedWeb of Science®Google Scholar 19 Owen HG, Brecher ME, Howard JF, Bandarenko N. Minimizing hypovolemic reactions with 3% hetastarch replacement during therapeutic plasma exchange. J Clin Apheresis 14: 91 (abstr). Web of Science®Google Scholar 20 Gross AG, Weinstein R. Pentastarch as partial replacement fluid for therapeutic plasma exchange: Effect on plasma proteins, adverse events during treatment, and serum ionized calcium. J Clin Apheresis 1999; 14: 114–121 10.1002/(SICI)1098-1101(1999)14:3<114::AID-JCA2>3.0.CO;2-8 PubMedWeb of Science®Google Scholar 21 Steinmuller DR. A dangerous error in the dilution of 25 percent albumin. N Engl J Med 1998; 338: 1226–1227 (letter). 10.1056/NEJM199804233381712 CASPubMedWeb of Science®Google Scholar 22 Pierce LR, Gaines A, Varricchio F, Epstein J. Hemolysis and renal failure associated with the inappropriate use of sterile water to dilute human albumin 25%. N Engl J Med 1998; 338: 1226–1227 PubMedWeb of Science®Google Scholar 23 Pierce LR, Gaines A, Finlayson JS, Varricchio F, Epstein JS. Hemolysis and acute renal failure due to the administration of albumin diluted in sterile water [letter]. Transfusion. 1999; 39: 110–111. 10.1046/j.1537-2995.1999.39199116905.x CASPubMedWeb of Science®Google Scholar 24 Bandarenko N, Brecher ME. United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis 1998; 13: 133–141. 10.1002/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z CASPubMedWeb of Science®Google Scholar Citing Literature Volume17, Issue42002Pages 207-211 ReferencesRelatedInformation
Publication Year: 2002
Publication Date: 2002-01-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 52
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot